Biotech companies, such as Generate Biomedicines and Montai, are utilizing artificial intelligence (AI) to enhance the drug development process. Generatehas trained their AI to design new proteins that do not exist in nature, expanding the scope of disease-treating proteins. They have already generated approximately 5 million of these proteins and are focusing on autoimmune conditions, cancer, and infectious diseases. The company's AI-assisted drugs for asthma and a COVID-19 monoclonal antibody treatment are entering the first phase of clinical trials. Similarly, Montai uses AI to analyze natural molecules and identify substances that could target specific pathways in the body. Over 125,000 potential substances have been identified for developing treatments for chronic illnesses. However, the success of these AI-assisted treatments will depend on clinical trials. While AI in drug development offers promise, it still requires significant human work and faces challenges such as data gaps and limitations.